Newswire (Published: Monday, November 13, 2017, Received: Thursday, November 9, 2017, 10:09:27 PM CST)

Word Count: 403

New Prostate Cancer Data Have Been Reported by P.N. Aguiar and Co-Authors (Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating in Santo Andre, Brazil, by NewsRx journalists, research stated, "To assess the cost-effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. An analytical decision model was developed to determine the cost-effectiveness of chemohormonal therapy versus androgen deprivation therapy alone in patients with metastatic hormone-sensitive prostate cancer and patients with non-metastatic high-risk prostate cancer."

The news reporters obtained a quote from the research, "The cost-effectiveness in metastatic patients with a high-volume disease was assessed separately. The model used data from randomized clinical trials and drug acquisition costs in Brazil. In addition, the costs of post-progression therapies have been included in this model. The benefits to health are expressed as the quality-adjusted life-years, and the incremental cost-effectiveness ratios were calculated. Chemohormonal therapy may be associated with improved quality-adjusted life-years for all patient. The improvement was more than six times greater for patients with high-volume metastatic disease. In these patients, the incremental cost-effectiveness ratios were up to 74% lower than the incremental cost-effectiveness ratios of patients with non-metastatic disease."

According to the news reporters, the research concluded: "Chemohormonal therapy has been more cost-effective in patients with high-volume metastatic disease."

For more information on this research see: Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. Einstein, 2017;15(3):349-354 (see also Oncology - Prostate Cancer).

Our news correspondents report that additional information may be obtained by contacting P.N. Aguiar, Faculdade de Medicina do ABC, Santo Andre, SP, Brazil. Additional authors for this research include C.MN. Barreto, B.S. Gutierres, H. Tadokoro and G.L Lopes.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1590/s1679-45082017gs4017. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Brazil, Hormones, Oncology, Santo Andre, South America, Prostate Cancer, Drugs and Therapies, Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

South America
Brazil
Americas

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Treatments and Therapies
            Medicinal Drugs